Australia

Thu
24
Sep

Cannabis regulation and policy in Australia

MCN speaks with Australia’s Therapeutic Goods Administration about medical cannabis regulation and access.

Tue
22
Sep

Will Australia Follow US Lead In Selling CBD?

Just how big is the market for low-dose CBD medication? Australia’s leading industry data source reports that 20% of patients are taking low-dose CBD.

Australians might be looking at a cleared path to cannabis medications as soon as next year. 

The Australian government made an interim decision earlier this month (Sept. 9) to bring low-dose CBD medication over-the-counter.

Thu
17
Sep

Australia unprepared for over-the-counter medical cannabis sales

Professor Iain McGregor from the Lambert Initiative says it is time for Australia to have a mature approach to consumer access to safe and effective cannabinoid products without a prescription.

New analysis by the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney shows that access to products containing cannabidiol in Australia is far more difficult than in many other countries.

Cannabidiol (CBD) is a non-intoxicating component of the hemp plant. Evidence suggests it has beneficial effects in treating conditions such as epilepsy, anxiety, pain and insomnia while carrying few, if any, risks of major side effects or addiction. CBD is now approved as a medicine to treat certain rare types of epilepsy in children.

Wed
16
Sep

Medical cannabis trial underway for Australian football players with chronic pain

For Australian football player Ryan Gale, his previous years of athletic glory have been replaced by a harsh new reality.

Gales lives with chronic pain due to his injuries and required a hip replacement at just 33-years-old.

“I don’t think I ever went one week without pain somewhere,” Gale told 7NEWS.

Mon
14
Sep

Australian Research To Study CBD For Spinal Injury Chronic Pain

Researchers at the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics and Brain and Mind Centre will investigate whether cannabidiol is an effective alternative for treating chronic pain caused by spinal injury.

The research team has been awarded $1.7 million to support the project, made up of  $1.45 million from NSW Health and $350,000 from the University.

The study’s lead investigator, Professor Luke Henderson – an expert in human brain imaging and pain, says half of spinal cord injury patients will develop chronic pain and current treatment options have been proven ineffective. Not only that, these treatments can introduce side effects making the condition worse.

Fri
11
Sep

Australian government considers over-the-counter access to medicinal cannabis in 2021

Medicinal cannabis could be purchased over the counter in Australian pharmacies from next year.

The Australian Department of Health's Therapeutic Goods Administration (TGA) announced they intend to make cannabidiol (CBD) medicines available without a prescription.

The interim decision was released in a report on Wednesday with a suggested implementation date of June 2021.

Cannabidiol is one of the main ingredients in cannabis and is used for medicinal purposes. 

In Australia, it is currently listed as a "prescription only medicine".

The proposed changes would save Australians a trip to the doctor and they would now be able to access cannabidiol after consulting a pharmacist.

Fri
04
Sep

More Australians back legalizing cannabis and 57 per cent support pill testing, national survey shows

A growing number of Australians support the legalization of cannabis, while almost three in five back the idea of pill testing, according to a new national survey.

The 2019 National Drug Strategy Household Survey also shows Australians are drinking and smoking less, but some illicit drug use is on the rise.

Importantly, this national snapshot, released on Thursday, shows the Australian community is becoming more open to less punitive measures around drug use.

Tue
11
Aug

Australia: TGA Approves Record Number Of Medical Cannabis Applications

Australia’s Therapeutic Goods Administration (TGA) had a busy July in relation to approving applications for medicinal cannabis products.

Australia’s Special Access Scheme (SAS) enables suitably authorised health practitioners to access therapeutic products not included in the Australian Register of Therapeutic Goods (ARTG). The only cannabis product currently included in the ARTG is Sativex (nabiximols), which contains THC (tetrahydrocannabinol) and CBD (cannabidiol).

There are several different pathways to gaining approval for cannabis medications through the SAS – categories A, B and C. Medical cannabis applications are generally via the Category B pathway.

Fri
07
Aug

WA Medical Cannabis Partnership Announced

Some doctors in Western Australian and their patients should have easier and faster access to medical cannabis resulting from a deal signed between Jupiter Health Clinics and Montu.

Founded in 2011, Jupiter Health and Medical Services is a network of more than 300 doctors in 30 medical practices across the state, and is one of the largest networks of GPs in Western Australia.

Montu works with doctors in Australia to support them in developing pathways to medical cannabis access for their patients. It also has a brand of medical cannabis products called “Circle” that are produced as part of a white label agreement with Canadian licensed producer, Aleafia Health Inc.

Wed
05
Aug

About 15 per cent of young Australians would try weed… if it was legal, that is

A clear majority of young people in Australia have never tried cannabis, but about one in seven would be open to giving it go if the plant was legalized, according to the results of a survey.

That was the finding of a recent study by researchers from the University of Queensland’s National Centre for Youth Substance Use Research and the School of Psychology, who considered poll data from 3,000-plus adolescents and young adults, according to the university.

Pages

Subscribe to RSS - Australia